alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 401–425 of 1,426 studies scoring ≤ 29 out of 100 (page 17 of 58) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Multiple-Dose Results from an Ongoing Phase 1 Study of Mivelsiran, an Investigational RNA Interference Therapeutic Targeting Amyloid-Beta Precursor Protein for Alzheimer's Disease

⚠ Conference abstract — not peer-reviewed alzhub usefulness score 16 out of 100. Alzheimer's & Dementia (AAIC 2025 conference abstract) 2025

Mivelsiran takes a completely different approach from antibody drugs: it's injected into the spinal fluid and uses RNA interference to tell brain cells to make less of the amyloid precursor protein in the first place, rather than clearing plaques after they form. 5 key findings →

Design: phase-1-trial Participants: 19 Evidence: preliminary

Full summary, score breakdown and related studies → Original source

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints (ReThink-ALZ)

⚠ Press release — not a study alzhub usefulness score 16 out of 100. GlobeNewswire (company press release); trial registered as NCT04994483 2024-11-25

This was the pivotal, large-scale trial meant to prove whether simufilam, a controversial experimental Alzheimer's drug, actually works. 5 key findings →

Design: phase-3-trial Participants: 804 Evidence: null result

Full summary, score breakdown and related studies → Original source

Retraction Note: A specific amyloid-beta protein assembly in the brain impairs memory

⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. Nature 2024-06-24

Eighteen years after it was published, Nature formally retracted the landmark 2006 paper that had proposed a specific amyloid protein (Aβ*56) as a cause of memory loss in mice, citing evidence of image manipulation, including splicing, duplication, and use of an image-editing 'eraser' tool. 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source

SEC Charges Cassava Sciences and Former Top Executives with Securities Fraud Related to Alzheimer's Drug Clinical Trial

⚠ Regulatory decision — not a study alzhub usefulness score 16 out of 100. SEC Press Release / Administrative Order (Securities Act of 1933 Release No. 11311) 2024-09-26

In September 2024 the SEC announced that Cassava Sciences and three individuals tied to the company agreed to pay over $40 million combined to settle federal charges that they misled investors about a 2020 Phase 2 trial of simufilam. 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source

RETRACTED: Hesperetin, a Citrus Flavonoid, Attenuates LPS-Induced Neuroinflammation, Apoptosis and Memory Impairments by Modulating TLR4/NF-κB Signaling

⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. Nutrients 2019-03-17

Glial activation and neuroinflammation play significant roles in apoptosis as well as in the development of cognitive and memory deficits. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2019-12-15

OASIS-3 is a compilation of MRI and PET imaging and related clinical data for 1098 participants who were collected across several ongoing studies in the Washington University Knight Alzheimer Disease Research Center over the course of 15 years. 4 key findings →

Design: longitudinal study Participants: 1,098 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial

⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. Archives of internal medicine 2005-08-01

Elderly patients with AD hypovitaminosis D are at increased risk for hip fracture. 3 key findings →

Participants: 29 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial

⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. The Kurume medical journal 2011-01-01

A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. 2 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology

⚠ Report — not peer-reviewed alzhub usefulness score 16 out of 100. Health technology assessment (Winchester, England) 2005-03-01

Further research with DEMQOL is needed to confirm these findings in an independent sample, evaluate responsiveness, investigate the feasibility of use in specific subgroups and in economic evaluation, and develop population norms. 2 key findings →

Participants: 130 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Retracted: Internet-Based Supportive Interventions for Family Caregivers of People With Dementia: Systematic Review and Meta-Analysis

⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. Journal of medical Internet research 2020-09-09

Future studies are encouraged to adopt personalized internet-based supportive interventions to improve the health of family caregivers and their care recipients. 3 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation

⚠ Report — not peer-reviewed alzhub usefulness score 16 out of 100. Health technology assessment (Winchester, England) 2013-02-01

The results presented are sufficiently encouraging to recommend that the DEMQOL instruments be used alongside a generic measure such as the European Quality of Life-5 Dimensions (EQ-5D) in future studies of interventions in dementia as there was evidence that they can be more sensitive for patients at the milder end of disease and some limited evidence that the person with dementia measure may be able to reflect deterioration. 2 key findings →

Design: clinical trial Participants: 644 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diagnostic performance of plasma Aβ 1-42 , Aβ 1-40 and pTau 181 in the LUMIPULSE automated platform for the detection of Alzheimer disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2023-04-26

Recently-developed blood markers for Alzheimer’s (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories. 4 key findings →

Participants: 136 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Down syndrome postmortem brains exhibit reduction in [ 18 F]nifene binding to α4β2* nicotinic acetylcholinergic receptors

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-09-15

Alzheimer’s disease (AD) pathology including amyloid beta (Aβ) plaques and tau tangles accumulate with age in Down Syndrome (DS). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Oligodendrocyte Enriched Brain Organoids Reveal Impaired Oligodendroglial Maturation and Altered Neural Network Activity in Down Syndrome

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-08-28

Individuals with Down syndrome (DS) display developmental delay, intellectual disability, premature brain ageing, and an increased risk of Alzheimer-like neurodegeneration. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-dimensional attention framework for personalised Alzheimer's disease progression prediction across sporadic and genetic risk cohorts

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-03

Alzheimer's disease progresses heterogeneously across diverse cohorts, yet current predictive models fail to capture this complexity while remaining clinically interpretable. 4 key findings →

Design: longitudinal study Participants: 1,669 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Multi-dimensional attention framework for personalized Alzheimer’s disease progression prediction across sporadic and genetic risk cohorts

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-12-17

Alzheimer’s disease manifests through heterogeneous progression patterns across diverse populations, yet current predictive models fail to capture this complexity while maintaining clinical interpretability. 4 key findings →

Design: longitudinal study Participants: 1,669 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A head-to-head comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-03-19

Adults with Down syndrome carry high risk of developing Alzheimer’s disease and efforts to include this population in clinical trials remain limited. 4 key findings →

Design: longitudinal study Participants: 237 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A disease similarity approach identifies short-lived Niemann-Pick type C disease mice with accelerated brain aging as a novel mouse model for Alzheimer’s disease and aging research

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2024-04-23

Since its first description in 1906 by Dr. Alois Alzheimer, Alzheimer’s disease (AD) has been the most common type of dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed